This website uses cookies in order to maximize its functionality and to provide you with better user experience.

Closing this window or continuing to navigate in the website means that you understand and accept the use of cookies in the website. 

Close
Roche Navigation Menu Roche4Med : Roche4Med
  • Sign in
  • Logout
  • Search
Roche
  • Up
  • Home
  • Search
  • Close search

						
							

Searching

    • Home
    • Products
      Products Overview
    • Congresses & Events
      Congresses & Events Overview
    • Comprehensive Genomic Profiling
      Comprehensive Genomic Profiling Overview
    Close

    1 - of results for ""

    No results

    Are you registered? Register now to view Roche scientific information for HCPs!

    • Clinical Data

      Read more

    • Tecentriq®
    • Mechanism of Action
    • Clinical Data
      • Non-small cell lung cancer
    • Dosing & Administration
    • AR Management
    • Resources
      • Professional Resources
      • Congresses
    • Safety Information
    • References
    • More
      • Mechanism of Action
      • Clinical Data
      • Dosing & Administration
      • AR Management
      • Resources
      • Safety Information
      • References

    You are here:

    1. Products
    2. Tecentriq®
    3. Clinical Data
    4. Non-small cell lung cancer
    5. NSCLC Safety Profile

    Safety Profile

    A FAVOURABLE SAFETY PROFILE WITH LOW TOXICITY

     

    Low incidence of ≥grade 3 treatment-related AEs1 

    Most common AEs All grades (%) Grades 3-4 (%)
    Fatigue 26.8 2.8
    Decreased appetite 23.5 0.3
    Cough 23.2 0.3
    Nausea 17.7 0.7
    Diarrhoea
    15.4 0.7
    Asthenia
    19 1.3
    Dyspnoea
    19.4 2.5
    Anemia 11.5 2.3
    Constipation 17.6 0.3
    Pyrexia
    17.7 0.2
    Vomiting 12.2 0.3
    Arthralgia 12 0.5

    AEs=adverse events

    *Includes reports of rash maculopapular, erythema, rash pruritic, dermatitis acneiform, eczema, rash papular, rash macular, dermatitis, rash erythematous, acne, skin exfoliation, skin ulcer, seborrhoeic dermatitis, erythema multiforme, dermatitis bullous, rash generalised, skin toxicity, dermatitis allergic, dermatitis exfoliative, palmar-plantar erythrodysaesthesia syndrome, rash papulosquamous, toxic skin eruption, erythema of eyelid, eyelid rash, folliculitis, furuncle, and rash.

     

    Low incidence of immune-related AEs1

    Immune-related AEs  All grades (%) Grades 3-4 (%)
    Pneumonitis 1 0.7
    Hepatitis 0.3 0.3
    Colitis 0.3 0

    Endocrinopathies

     Hypothyroidism

     Hyperthyroidism

     Adrenal insufficiency

     Diabetes mellitus

     Hypophysitis

     

    3

    1.1

    0.3

    0.2

    0.2

     

    0

    0

    0

    0

    0

    Meningoencephalitis

     Meningitis

     Encephalitis

     

    0.5

    0.2

     

    0

    0

    Pancreatitis
    0.2 0.2
    Peripheral neuropathy 3.9 0

    Related Links

    OAK Study Design

    Safety Profile

    Dosing and Administration

     

    References:  

    1. Rittmeyer A, Barlesi F, Waterkamp D, et al; OAK Study Group. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK):
    a phase 3, open-label, multicentre randomised controlled trial [published online December 12, 2016] [supplementary appendix]. Lancet.doi:10.1016/S0140-6736(16)32517-X.

     

    MatCode Approval No.: -1905-V2-3253

    Share
    Close

    Important notice!

    This website is intended for the use of healthcare professionals only, Please approve that you are a healthcare professional in order to continue using this website.

    Accept Cancel
    • © 2021 Roche Pharmaceuticals (Israel) Ltd.
    • 03.08.2020
    • Legal Information

    • Find us on YouTube